Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinical Genitourinary Cancer|March 18, 2014
Papillary renal cell carcinoma: current progress and future directionsPrzemyslaw W Twardowski, Philip C Mack, Primo N Lara
Cancer Investigation|January 9, 2008
Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxibPrzemyslaw W Twardowski, Leslie Smith-Powell, Mary Carroll, et al.
Cancers|February 11, 2023
Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical TrialsXiaoqiang Wang, Yin S Chan, Kelly Wong, et al.
Anti-Cancer Drugs|May 9, 2013
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapyPrzemyslaw W Twardowski, Jan H Beumer, C S Chen, et al.
Cancer Medicine|August 9, 2024
Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancerAlberto Mendoza-Valderrey, Jane Choe, Daria M Kessler, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw W Twardowski, Catherine M Tangen, Xiwei Wu, et al.
BJU International|November 6, 2009
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urotheliumDaniel P Petrylak, Catherine M Tangen, Peter J Van Veldhuizen, et al.
Journal of the National Cancer Institute|February 26, 2014
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421Primo N Lara, Benjamin Ely, David I Quinn, et al.
Current Problems in Cancer|May 8, 2026
Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinomaAnishka A D'Souza, Susan G Groshen, Denice Tsao-Wei, et al.
The Journal of Urology|October 22, 2020
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical DataE David Crawford, Jason M Hafron, Scott T Tagawa, et al.
Pageof 2